Merck & Company Inc (MRK)vsProfound Medical Corp (PROF)
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
PROF
Profound Medical Corp
$7.22
-0.69%
HEALTHCARE · Cap: $262.04M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 408448% more annual revenue ($65.77B vs $16.10M). MRK leads profitability with a 13.6% profit margin vs -264.4%. MRK earns a higher WallStSmart Score of 53/100 (C-).
MRK
Buy53
out of 100
Grade: C-
PROF
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Intrinsic value data unavailable for PROF.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
Revenue surging 43.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -67.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bull Case : PROF
The strongest argument for PROF centers on Revenue Growth, Debt/Equity. Revenue growth of 43.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : PROF
The primary concerns for PROF are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while PROF is a hypergrowth play — different risk/reward profiles.
PROF carries more volatility with a beta of 0.50 — expect wider price swings.
PROF is growing revenue faster at 43.1% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (53/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Profound Medical Corp
HEALTHCARE · MEDICAL DEVICES · USA
Profound Medical Corp. The company is headquartered in Mississauga, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?